AnnJi

Biotech company AnnJi is moving its drug candidate AJ201 into a Phase 3 clinical trial for Kennedy's disease, a rare genetic neuromuscular disorder also known as spinal and bulbar muscular atrophy. The advance marks a significant step in developing a treatment for a condition that currently has no approved cure. Details on trial design and timing have not been released.